Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
Tóm tắt
Từ khóa
Tài liệu tham khảo
Trousseau A: Phlegmana alba dolens. Clinic Med de l’Hotel-Dieu. 1985, 3: 654-712.
Levin J, Conley CL: Thrombocytosis associated with malignant disease. Arch Intern Med. 1964, 114: 497-500. 10.1001/archinte.1964.03860100079008.
Leslie M: Cell biology: beyond clotting: the powers of platelets. Science. 2010, 328: 562-564. 10.1126/science.328.5978.562.
Borsig L: The role of platelet activation in tumor metastasis. Expert Rev Anticancer Ther. 2008, 8: 1247-1255. 10.1586/14737140.8.8.1247.
Labelle M, Begum S, Hynes RO: Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011, 20: 576-590. 10.1016/j.ccr.2011.09.009.
Buergy D, Wenz F, Groden C, Brockmann MA: Tumor-platelet interaction in solid tumors. Int J Cancer. 2012, 130: 2747-2760. 10.1002/ijc.27441.
Bambace NM, Holmes CE: The platelet contribution to cancer progression. J Thromb Haemost. 2011, 9: 237-249. 10.1111/j.1538-7836.2010.04131.x.
Goubran HA, Burnouf T, Radosevic M, El-Ekiaby M: The platelet-cancer loop. Eur J Intern Med. 2013, 24: 393-400. 10.1016/j.ejim.2013.01.017.
Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J, Deavers MT, Vasquez HG, Urbauer D, Landen CN, Hu W, Gershenson H, Matsuo K, Shahzad MM, King ER, Tekedereli I, Ozpolat B, Ahn EH, Bond VK, Wang R, Drew AF, Gushiken F, Lamkin D, Collins K, DeGeest K, Lutgendorf SK, et al: Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012, 366: 610-618. 10.1056/NEJMoa1110352.
Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009, 27: 5794-5799. 10.1200/JCO.2008.21.4809.
Sasaki K, Kawai K, Tsuno NH, Sunami E, Kitayama J: Impact of preoperative thrombocytosis on the survival of patients with primary colorectal cancer. World J Surg. 2012, 36: 192-200. 10.1007/s00268-011-1329-7.
Wan S, Lai Y, Myers RE, Li B, Hyslop T, London J, Chatterjee D, Palazzo JP, Burkart AL, Zhang K, Xing J, Yang H: Preoperative platelet count associates with survival and distant metastasis in surgically resected colorectal cancer patients. J Gastrointest Cancer. 2013, 44: 293-304. 10.1007/s12029-013-9491-9.
Yu D, Liu B, Zhang L: Platelet count predicts prognosis in operable non-small cell lung cancer. Exp Ther Med. 2013, 5: 1351-1354.
Wang H, Gao J, Bai M, Liu R, Li H, Deng T, Zhou L, Han R, Ge S, Huang D, Ba Y: The pretreatment platelet and plasma fibrinogen level correlate with tumor progression and metastasis in patients with pancreatic cancer. Platelets. 2013, doi:10.3109/09537104.2013.827782
Hwang SJ, Luo JC, Li CP, Chu CW, Wu JC, Lai CR, Chiang JH, Chau GY, Lui WY, Lee CC, Chang FY, Lee SD: Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol. 2004, 10: 2472-2477.
Carr BI, Guerra V: Features of massive hepatocellular carcinomas. Eur J Gastroenterol Hepatol. 2013, doi:10.1097/MEG.0b013e3283644c49
Carr BI, Guerra V: Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci. 2013, 58: 1790-1796. 10.1007/s10620-012-2527-3.
Carr BI, D’Alessandro R, Refolo MG, Lippolis C, Cavallini A, Messa C: Effects of Pheripheral Blood Platelets on HCC Cell Growth, Migration and Invasion. The Liver Meeting Proc. 2013, Boston, MA, USA: AASLD
Carr BI, Cavallini A, Lippolis C, D’Alessandro R, Messa C, Refolo MG, Tafaro A: Fluoro- Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol. 2013, 228: 292-297. 10.1002/jcp.24148.
D’Alessandro R, Refolo MG, Lippolis C, Messa C, Cavallini A, Rossi R, Resta L, Di Carlo A, Carr BI: Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemother Pharmacol. 2013, 72: 869-877. 10.1007/s00280-013-2269-8.
Dashevsky O, Varon D, Brill A: Platelet-derived microparticles promote invasiveness of prostate cancer cells via upregulation of MMP-2 production. Int J Cancer. 2009, 124: 1773-1777. 10.1002/ijc.24016.
Demers M, Wagner DD: Targeting platelet function to improve drug delivery. Oncoimmunology. 2012, 1: 100-102. 10.4161/onci.1.1.17962.
Demers M, Ho-Tin-Noé B, Schatzberg D, Yang JJ, Wagner DD: Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res. 2011, 71: 1540-1549. 10.1158/0008-5472.CAN-10-2038.
Song S, Wientjes MG, Gan Y, Au JL: Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A. 2000, 97: 8658-8663. 10.1073/pnas.140210697.
Shen K, Cui D, Sun L, Lu Y, Han M: Inhibition of IGF-IR increases chemosensitivity in human colorectal cancer cells through MRP-2 promoter suppression. J Cell Biochem. 2012, 113: 2086-2089. 10.1002/jcb.24080.
Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AK, Gans RO, de Vries EG: Metformin: taking away the candy for cancer?. Eur J Cancer. 2010, 46: 2369-2380. 10.1016/j.ejca.2010.06.012.
Atzori F, Traina TA, Ionta MT, Massidda B: Targeting insulin-like growth factor type 1 receptor in cancer therapy. Target Oncol. 2009, 4: 255-266. 10.1007/s11523-009-0123-z.
Kina S, Phonaphonh T, Liang F, Kuang H, Arasaki A, Arakaki K, Nakasone T, Sunakawa H: PDGFα receptor is a mediator for cisplatin-induced Met expression. Eur J Pharmacol. 2013, 699: 227-232. 10.1016/j.ejphar.2012.11.014.
Zhou T, Duan J, Wang Y, Chen X, Zhou G, Wang R, Fu L, Xu F: Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells. Tumour Biol. 2012, 33: 1299-1306. 10.1007/s13277-012-0377-4.
Peer D, Dekel Y, Melikhov D, Margalit R: Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res. 2004, 64: 7562-7569. 10.1158/0008-5472.CAN-03-4046.
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64: 7099-7109. 10.1158/0008-5472.CAN-04-1443.
Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 2006, 66: 11851-11858. 10.1158/0008-5472.CAN-06-1377.
Hikita H, Takehara T, Shimizu S, Kodama T, Shigekawa M, Iwase K, Hosui A, Miyagi T, Tatsumi T, Ishida H, Li W, Kanto T, Hiramatsu N, Hayashi N: The Bcl-xL inhibitor, ABT- 737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology. 2010, 52: 1310-1321. 10.1002/hep.23836.
Galmiche A, Ezzoukhry Z, François C, Louandre C, Sabbagh C, Nguyen-Khac E, Descamps V, Trouillet N, Godin C, Regimbeau JM, Joly JP, Barbare JC, Duverlie G, Mazière JC, Chatelain D: BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol Cancer Res. 2010, 8: 1116-1125. 10.1158/1541-7786.MCR-10-0029.
Shimizu S, Takehara T, Hikita H, Kodama T, Tsunematsu H, Miyagi T, Hosui A, Ishida H, Tatsumi T, Kanto T, Hiramatsu N, Fujita N, Yoshimori T, Hayashi N: Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer. 2012, 131: 548-557. 10.1002/ijc.26374.
Ezzoukhry Z, Louandre C, Trécherel E, Godin C, Chauffert B, Dupont S, Diouf M, Barbare JC, Mazière JC, Galmiche A: EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer. 2012, 131: 2961-2969. 10.1002/ijc.27604.
Louandre C, Ezzoukhry Z, Godin C, Barbare JC, Mazière JC, Chauffert B, Galmiche A: Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib. Int J Cancer. 2013, 133: 1732-4172. 10.1002/ijc.28159.
Liu Y, Liu A, Li H, Li C, Lin J: Celecoxib inhibits interleukin-6/interleukin-6 receptor- induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. Cancer Prev Res (Phila). 2011, 4: 1296-1305. 10.1158/1940-6207.CAPR-10-0317.
Dai Y, Grant S: Targeting multiple arms of the apoptotic regulatory machinery. Cancer Res. 2007, 67: 2908-2911. 10.1158/0008-5472.CAN-07-0082.
Sitia G, Iannacone M, Guidotti LG: Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. J Hepatol. 2013, 4: doi:S0168- 8278(13)00373-5